The efficacy of faecal microbiota transplantation (FMT) in Crohn’s disease (CD) remains unclear due to lack of data. This study aimed to assess the value of FMT in treating CD‐related clinical targets. The use of FMT for CD as a registered trial (NCT01793831) was performed between October 2012 and December 2017. Seven therapeutic targets included abdominal pain, diarrhoea, hematochezia, fever, steroid‐dependence, enterocutaneous fistula and active perianal fistula. Each target was recorded as 1 (yes) or 0 (no) during the long‐term follow‐up for each patient. The primary outcome was the rate of improvement in each therapeutic target. Overall, 174 patients completed the follow‐up. The median follow‐up duration was 43 (interquartile range, 28–59) months. The median score of the total targets was 2 (range, 1–4) before FMT, and it decreased significantly at 1, 3, 6, 12, 24 and 36 months after FMT (P < 0.001 respectively). At 1 month after FMT, 72.7% (101/139), 61.6% (90/146), 76% (19/25) and 70.6% (12/17) of patients achieved improvement in abdominal pain, diarrhoea, hematochezia and fever respectively. Furthermore, 50% (10/20) of steroid‐dependent patients achieved steroid‐free remission after FMT. The present findings indicate that it is important to understand the efficacy of FMT in CD as a targeted therapy, especially for abdominal pain, hematochezia, fever and diarrhoea.

中文翻译：

---

粪便微生物群移植治疗克罗恩病的疗效：新的靶向治疗？

由于缺乏数据，粪便微生物群移植（FMT）对克罗恩病（CD）的疗效仍不清楚。本研究旨在评估 FMT 在治疗 CD 相关临床靶标中的价值。使用 FMT 治疗 CD 的注册试验（NCT01793831）于 2012 年 10 月至 2017 年 12 月进行。七个治疗目标包括腹痛、腹泻、便血、发热、类固醇依赖性、肠皮瘘和活动性肛周瘘。在每位患者的长期随访过程中，每个目标均记录为 1（是）或 0（否）。主要结果是每个治疗目标的改善率。总体而言，174 名患者完成了随访。中位随访时间为 43 个月（四分位数间距，28-59）个月。FMT前总目标得分中位数为2分（范围1~4），FMT后1、3、6、12、24和36个月显着下降（分别P  < 0.001）。FMT后1个月，72.7%（101/139）、61.6%（90/146）、76%（19/25）和70.6%（12/17）的患者腹痛、腹泻、便血和发热得到改善分别。此外，50% (10/20) 的类固醇依赖患者在 FMT 后达到无类固醇缓解。目前的研究结果表明，了解 FMT 作为靶向治疗在克罗恩病中的疗效非常重要，特别是对于腹痛、便血、发烧和腹泻。